ACCESS-AD: a new European initiative to accelerate timely and equitable AD diagnosis, treatment and care
image: The ACCESS-AD Project view more Credit: ACCESS-AD Amsterdam, 13 January 2026. Today, the ACCESS-AD consortium is announcing…
AI is speeding into healthcare. Who should regulate it? — Harvard Gazette
AI is moving quickly into healthcare, bringing potential benefits but also possible pitfalls such as bias that drives…
1000 days of war deepen the world’s worst health and humanitarian crisis
Today, the conflict in Sudan reaches its 1000th day, with over 20Â million people requiring health assistance and 21Â million…
The future of healthcare data: How agent-to-agent communication is reshaping medical systems
In practice, that could mean a digital assistant automatically scheduling a follow-up appointment, checking insurance coverage, sharing lab…
The system is chronically ill. Where are the doctors?
This is a bird’s eye view of the shortfalls in medical sector regulation in India. A spurt of…
‘He tried so hard to get help’: the tragic results of NHS right-to-choose for ADHD patients | Attention deficit hyperactivity disorder
When Leigh White remembers her brother Ryan, she thinks of a boy of extraordinary ability who “won five…
What’s Actually Going On In Your Body
When you think of people with sleep apnea, maybe you picture loud, cartoonish snoring, or assume you’d know…
The next 3 years could be huge for this ASX healthcare stock. Here’s why
Image source: Getty Images An ASX healthcare stock is back in focus today after a fresh update lifted…
how the experts avoid high blood pressure
When did you last check your blood pressure? Despite awareness campaigns, one survey commissioned by NHS England found…
3 quality ASX healthcare shares worth buying now
Image source: Getty Images These 3 ASX healthcare shares have all had their fair share of issues over…
Dr AI unlikely to replace GPs any time soon – The Irish Times
Artificial intelligence (AI) has the potential to revolutionise patient care, but should it be used by the public…
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?
The gap may be too hard to close in the next 12 months. Novo Nordisk (NVO 0.47%) was…